Market Overview

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Co-Diagnostics, Inc. (CODX)

Share:

LOS ANGELES, Aug. 10, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming August 17, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ:CODX)  investors who purchased securities between February 25, 2020 and May 15, 2020, inclusive (the "Class Period").

If you suffered a loss on your Co-Diagnostics investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/co-diagnostics-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On February 24, 2020, Co-Diagnostics announced that it had received regulatory clearance to sell its COVID-19 tests in the European Community.

Then on April 6, 2020, the Company announced that it had received emergency use authorization for its tests from the U.S. Food and Drug Administration ("FDA").

Finally, on May 14, 2020, after the Company continued to uphold its statements about the success of its test in its first quarter results, public reports began to circulate, questioning the Company's claims of 100% accuracy because the Company was hesitant to participate in U.S.-based testing. Later in the day, the U.S. FDA stated publicly that no COVID-19 test is 100% accurate.

On this news, the Company's share price fell $5.06, or over 22%, to close at $17.07 per share on May 15, 2020, thereby injuring investors.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Co-Diagnostics securities during the Class Period, you may move the Court no later than August 17, 2020 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com.  If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/glancy-prongay--murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-co-diagnostics-inc-codx-301108562.html

SOURCE Glancy Prongay & Murray LLP

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com